secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2021-10-08T23:59:59+00:00
Accession:  0001193805-21-001429
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Kenneth A. Clark, partner at WSGR, to Board; Erdtmann resigns
--------------------------------------------------------------------------------

- Kenneth A. Clark elected to board of directors, effective October 7, 2021.
- Clark is a partner at Wilson Sonsini Goodrich & Rosati, specializing in biotech strategic M&A and financing.
- Ramses Erdtmann resigned to pursue other opportunities; resignation not due to any disagreement with the company.
- Clark appointed to Audit, Compensation, and Nominating and Corporate Governance Committees.
- Received grant of stock options under Summit's non-employee director compensation policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119380521001429/0001193805-21-001429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119380521001429/e620998_8k-summit.htm
  HTML page:      https://secwatch.observer/filing/0001193805-21-001429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer